Isolation and characterisation of degradant impurities in Dipyridamole formulation

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 256-264

  Venkata Subbaiah, B ^a   Sree Ganesh, K K ^a   Vamsi krishna, G ^a   Vyas, K ^a   Vasu Dev, R ^b   Subramanyam Reddy, K ^c  

^a DR REDDY'S LABORATORIES LTD   (India)

^b Pharmaceutical Development   (India)

^c SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Characterisation techniques; Degradant impurities; Dipyridamole; Isolation; Preparative HPLC

Indexed keywords

2,2',2'',2''' [4 HYDROXY 8 (PIPERIDIN 1 YL) PYRIMIDO [5,4 D]PYRIMIDINE 2,6 DIYL]BIS(AZANETRIYL)TETRAETHANOL; 4 [2 [[6 [BIS(2 HYDROXYETHYL)AMINO] 4, 8 BIS(PIPERIDIN 1 YL)PYRIMIDO[5,4 D]PYRIMIDIN 2 YL](2 HYDROXYETHYL)AMINO]ETHOXY] 2, 3 DIHYDROXY 4 OXOBUTANOIC ACID; DIPYRIDAMOLE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; DRUG IMPURITY; DRUG ISOLATION; DRUG STABILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MECHANICAL STRESS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DIPYRIDAMOLE; DRUG CONTAMINATION; TANDEM MASS SPECTROMETRY;

EID: 84856094664     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.028     Document Type: Article

References (19)

1. Stafford N.P., Pink A.E., White A.E., Glenn J.R., Heptinstall S. Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood, arterioscler. Thromb. Vasc. Biol. 2003, 23:1928-1933.
2. Chakrabarti S., Vitseva O., Iyu D., Varghese S., Freedman J.E. The effect of Dipyridamole on vascular cell-derived reactive oxygen species. J. Pharmacol. Exp. Ther. 2005, 315:494-500.
3. Kvien T.K., Fjeld E., Slatkowsky-Christensen B., Nichols M., Zhang Y., Proven A., et al. Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann. Rheum. Dis. 2008, 67:942-948.
4. Zimmermann G.R., Avery W., Finelli A.L., Farwell M., Fraser C.C., Borisy A.A. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res. Ther. 2009, 11:105-118.
5. Forrest C.M., Stone T.W., Mackay G.M., Oxford L., Stoy N., Harman G., et al. Purine metabolism and clinical status of patients with rheumatoid arthritis treated with Dipyridamole. Nucleosides Nucleotides Nucleic Acids 2006, 25:1287-1290.
6. Zhang J., Miller R.B., Jacobus R. Development and validation of a stability-indicating HPLC method for the determination of degradation products in Dipyridamole injection. Chromatographia 1997, 44:247-252.
7. Prakash K., Kalakuntla Rama Rao, Reddy Sama Jayapal Rapid and simultaneous determination of aspirin and Dipyridamole in pharmaceutical formulations by reversed-phase high performance liquid chromatography (RP-HPLC) method. Afr. J. Pharm. Pharacol. 2011, 5:244-251.
8. Bridle J.H., Brimble M.T. A stability indicating method for Dipyridamole. Drug Dev. Ind. Pharm. 1993, 19:371-381.
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q3A (R2), Impurities in New Drug substances 2006, 1-15.
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q3B (R2), Impurities in New Drug Products 2006, 1-16.
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use, ICH Q1A (R2) Stability Testing of New Drug Substances and Products 2003, 1-24.
12. U.S. Food and Drug Administration Drug Stability Guidelines, February 1987.
13. Görög S. New safe medicines faster: the role of analytical chemistry. Trends Anal. Chem. 2003, 22:407-415.
14. Mollica J.A., Ahuja S. Cohen, Stability of Pharmaceuticals. J. J. Pharm. Sci. 1978, 67:443-445.
15. The United States Pharmacopeia General notices 2000, United States Pharmacopeial Convention, Inc., Rockville, MD, USA, p. 7. 25th ed.
16. Satinder Ahuja, Karen Mills Alsante, Handbook of Isolation and Characterisation of Impurities in Pharmaceuticals, first ed., USA, 2003.
17. Smith R.J., Webb M.L. Analyses of Drug Impurities 2007, Blackwell Publishing, UK. first ed.
18. Ahuja S. Impurities Evaluation of Pharmaceuticals 1998, Marcel Dekker, NY. first ed.
19. Herbert Budzikiewicz, Carl Djerassi, Williams Dudley H. Mass spectrometry of organic compounds 1967, Holden-day, Inc., CA. first ed.